Hodgkin’s Lymphoma

  • Hans T. Chung
  • Stephen L. Shiao
  • Naomi R. Schechter


Epidemiology Incidence/mortality in the US for 2008 is 8,220/1,350. Males slightly greater than females (1.1:1). Bimodal peak: ages 25–30 and >55. First-degree relatives of patients have fivefold increase in risk for Hodgkin’s disease. Associated with Epstein–Barr virus, which is associated with mixed cellularity subtype. EBV DNA has been detected in Reed-Sternberg cells. Associated with HIV infection.


Slip Capital Femoral Epiphysis Bulky Disease Total Lymphoid Irradiation Extranodal Disease Stanford Versus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



  1. Advani R, Maeda L, Lavori P, et al. Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin’s Disease. J Clin Oncol 2007;25(25):3902–3907.PubMedCrossRefGoogle Scholar
  2. Aleman BM, Raemaekers JM, Tomasic R, et al. Involved field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 2007;67(1):19–30.PubMedCrossRefGoogle Scholar
  3. Aleman BMP, Raemaekers JMM, Tirelli U, et al. Involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med 2003;348:2396–2406.PubMedCrossRefGoogle Scholar
  4. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Eng J Med 1992;327:1478–1484.CrossRefGoogle Scholar
  5. Canellos GP, Niedzwiecki D. Long-term follow-up of Hodgkin’s disease trial. N Engl J Med 2002;346:1417–1418.PubMedCrossRefGoogle Scholar
  6. Carde P, Hagenbeek A, Hayat M, et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin’s disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1993;11:2258–2272.PubMedGoogle Scholar
  7. Diehl V, Brillant C, Engert A, et al. HD10: Investigating reduction of combined modality treatment intensity in early stage Hodgkin’s lymphoma. Interim analysis of a randomized trial of the German Hodgkin Study Group (GHSG). J Clin Oncol (Meeting abstracts) 2005a; 23:6506.Google Scholar
  8. Diehl V, Brillant C, Engert A, et al. Recent interim analysis of the HD11 trial of the GHSG: intensification of chemotherapy and reduction of radiation dose in early unfavorable stage Hodgkin’s lymphoma. Blood 2005b;106:(abstract no. 816)Google Scholar
  9. Diehl V, Franklin J, Pfistner B, et al. Ten-year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). J Clin Oncol (Meeting abstracts) 2007;25:LBA8015.Google Scholar
  10. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. NEJM 2003;348:2386–2395.PubMedCrossRefGoogle Scholar
  11. Diehl V, Franklin J, Tesch H, et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin’s disease in the HD9 trial of the German Hodgkin’s Lymphoma Study Group (GHSG). Proc ASCO 2007 (abstract no. 7).Google Scholar
  12. Diehl V, Haverkamp H, Mueller R, et al. Eight cycles of BEACOPP escalated compared with 4 cycles of BEACOPP baseline with or without readiotherapy in patients in advanced stage Hodgkin lymphoma (HL): final analysis of the HD12 trial of the Germa Hodgkin Study Group (GHSG). J Clin Oncol 2009;27:15s (Suppl; abstr 8544).CrossRefGoogle Scholar
  13. Diehl V, Loeffler M, Pfreundschuh M, et al. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin’s disease. German Hodgkins’ Study Group (GHSG). Ann Oncol. 1995;6(9):901–910.PubMedGoogle Scholar
  14. Eich H, Gossmann A, Engert A, et al. A contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin’s lymphoma – analysis of a quality control program initiated by the Radiotherapy Reference Center of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biol Phys 2007;69:1187–1192.PubMedCrossRefGoogle Scholar
  15. Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009;27(27):4548–4554.PubMedCrossRefGoogle Scholar
  16. Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 2003;21:3601–3608.PubMedCrossRefGoogle Scholar
  17. Engert, A, Franklin, J, Eich H, et al. Two cycles of doxorubicin, bleomycin, vinblastine and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: final results of the GHSG HD7 Trial. J Clin Oncol 2007;25(23): 3495–3502.PubMedCrossRefGoogle Scholar
  18. Fabian CJ, Mansfield CM, Dahlberg S, et al. Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study. Ann Intern Med 1994;120(11):903–912.PubMedCrossRefGoogle Scholar
  19. Ferme C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med 2007;357(19):1916–1927.PubMedCrossRefGoogle Scholar
  20. Ferme C, Sebban C, Hennequin C, et al. Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin’s disease: results of the Groupe d’etudes des Lymphomes de l’Adulte H89 trial. Blood 2000;95:2246–2252.PubMedGoogle Scholar
  21. Gallmini A, Hutchings M, Rigacci L, et al. Early Interim 2-[18F]Fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007;25:3746–3752.CrossRefGoogle Scholar
  22. Girinsky T, Specht L, Ghalibafian M, et al. The conundrum of Hodgkin lymphoma nodes: To be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. Radiother Oncol 2008;88:202–210.PubMedCrossRefGoogle Scholar
  23. Gobbi PG, Levis A, Chisesi T, et al. ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced stage Hodgkin’s lymphoma. Final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 2005;23:9198–9207.PubMedCrossRefGoogle Scholar
  24. Hasenclever D, Diehl V, Armitage JO, et al. A prognostic score for advanced Hodgkin’s disease. N Engl J Med 1998;339:1506–1514.PubMedCrossRefGoogle Scholar
  25. Horning SJ, Hoppe RT, Advani R, et al. Efficacy and late effects of Stanford V chemotherapy and radiotherapy in untreated Hodgkin’s disease: mature data in early and advanced stage patients. Blood 2004;104(abstr 308).Google Scholar
  26. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee on Internation Harmonization Project in Lymphoma. J Clin Oncol 2007;25(5):571–578.PubMedCrossRefGoogle Scholar
  27. Kobe C, Dietlein M, Franklin J et al. FDG-PET for assessment of residual tissue after completion of chemotherapy in Hodgkin lymphoma – report on the second interim analysis of the PET investigation in the trial HD15 of the GHSG. Haematologica 2007;92(Suppl 5):CO21.Google Scholar
  28. Laskar S, Gupta T, Vimal S, et al. Consolidation radiation after complete remission in Hodgkin’s disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol 2004;22:62–68.PubMedCrossRefGoogle Scholar
  29. Lavoie JC, Connors JM, and Phillips GL, et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 2005;106(4):1473–1478.PubMedCrossRefGoogle Scholar
  30. Macdonald DA, Ding K, Gospodarowicz MK, et al. Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma. Ann Oncol 2007;18(10):1680–1684.PubMedCrossRefGoogle Scholar
  31. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin’s lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:4634–4642.PubMedCrossRefGoogle Scholar
  32. Noordijk E, Carde P, Hagenbeek A. Combination of radiotherapy and chemotherapy is advisable in all patients with clinical stage I-II Hodgkin’s disease. Six-year results of the EORTC-GPMC controlled clinical trials “H7-VF”, “H7-F” and “H7-U”. Presented at ASTRO; 1997.Google Scholar
  33. Noordijk EM, Thomas J, Ferme C, et al. First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma (HL). J Clin Oncol (Meeting abstracts) 2005;23:6505.Google Scholar
  34. Noordijk, EM, Carde P, Dupouy N, et al. Combined-modality therapy for clinical stage I or II Hodgkin’s lymphoma: long-term results of the European Oranization for Research and Treatment of Cancer (EORTC) H7 randomized controlled trials. J Clin Oncol 2006;24:3128–3135.PubMedCrossRefGoogle Scholar
  35. Pavlovsky S, Maschio M, Santarelli MT, et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I–II Hodgkin’s disease. J Natl Cancer Inst 1988;80(18): 1466–1473.PubMedCrossRefGoogle Scholar
  36. Picardi M, De Renzo A, Pane F, et al. Randomized comparison of consolidation radiation versus observation in bulky Hodgkin’s lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma 2007;48(9):1721–1727.PubMedCrossRefGoogle Scholar
  37. Press OW, LeBlanc M, Lichter AS, et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin’s disease. J Clin Oncol 2001;19:4238–4244.PubMedGoogle Scholar
  38. Rigacci L, Vitolo U, Nassi L, et al. Positron emission tomography in the staging of patients with Hodgkin’s lymphoma. Ann Hematol 2007;86:897–903.PubMedCrossRefGoogle Scholar
  39. Sieber M, Franklin J, Tesch H. Two Cycles ABVD plus extended field radiotherapy is superior to radiotherapy alone in early stage Hodgkin’s disease: results of the German Hodgkin’s Lymphoma Study Group (GHSG) Trial HD7. Leuk Lymphoma 2002;43(Suppl 2):52.Google Scholar
  40. Sieniawski, M, Franklin J, Nogova, L et al. Outcome of patientS experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin’s Lymphoma. J Clin Oncol 2007;25(15):2000–2005.PubMedCrossRefGoogle Scholar
  41. Specht L, Gray RG, Clarke MJ, et al. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin’s disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin’s Disease Collaborative Group. J Clin Oncol 1998;16:830–843.PubMedGoogle Scholar
  42. Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004;104: 3483–3489.PubMedCrossRefGoogle Scholar
  43. Thomas J, Ferme C, Noordijk EM, et al. EORTC lymphoma group; groupe d’études des lymphomes adultes (GELA). Results of the EORTC-GELA H9 randomized trials: The H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma (HL). Haematologica 2007;92(s5):27.Google Scholar

Further Reading

  1. Bonadonna G, Bonfante V, Viviani S, et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol 2004;22: 2835–2841.PubMedCrossRefGoogle Scholar
  2. Carde P, Noordijk EM, Hagenbeek A, et al. Superiority of EBVP chemotherapy in combination with involved field irradiation (EBVP/IF) over subtotal nodal irradiation (STNI) in favorable clinical stage (CS) I-II Hodgkin’s disease: the EORTC-GPMC H7F randomized trial (Meeting abstract). J Clin Oncol 1997;16:16.Google Scholar
  3. Chisesi T, Federico M, Levis A, et al. ABVD versus stanford V versus MEC in unfavourable Hodgkin’s lymphoma: results of a randomised trial. Ann Oncol 2002;13(Suppl 1):102–106.PubMedCrossRefGoogle Scholar
  4. Cosset J. MOPP/ABV hybrid and irradiation in unfavourable supradiaphragmatic clinical stages I-II Hodgkin’s lymphoma: preliminary results of the EORTC-GELA H8-U randomized trial (no. 20931) in 995 patients. Leuk Lymphoma 2001;42:12.Google Scholar
  5. Girinsky T, van der Maazen, Specht L, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lumphoma: concepts and guidelines. Radiother Oncol 2006;79:270–277.PubMedCrossRefGoogle Scholar
  6. Sieber M, Tesch H, Pfistner B, et al. Treatment of advanced Hodgkin’s disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin’s Lymphoma Study Group HD6 trial. Ann Oncol 2004;15:276–282.PubMedCrossRefGoogle Scholar
  7. The NCCN Hodgkin Disease/Lymphoma Guidelines (Version 2.2008) in The Complete Library of NCCN Clinical Practice Guidelines in Oncology™ [CD-ROM] (March 2009). Fort Washington, Pennsylvania: © 2008 National Comprehensive Cancer Network, Inc; 2009.Google Scholar

Copyright information

© Springer-Verlag New York 2010

Authors and Affiliations

  • Hans T. Chung
    • 1
  • Stephen L. Shiao
    • 2
  • Naomi R. Schechter
    • 2
  1. 1.Radiation Oncology, Sunnybrook Odette Cancer CentreUniversity of TorontoTorontoCanada
  2. 2.Radiation OncologyUniversity of California San FranciscoSan FranciscoUSA

Personalised recommendations